Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRSA nasal decolonization evaluation with mupirocin and chlorhexidine
2010-020206-14Phase 4Terminated
- Sponsor
- St George's, University of London
- Start
- Aug 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mupirocin and chlorhexidine in Staphylococcus aureus infection, sponsored by St George's, University of London. Primary endpoint: Eradication of nasal Staphylococcus aureus at 30 days. Started Aug 2010; status: terminated.
02
Drugs
mupirocinchlorhexidine
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on 2010-020206-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020206-14.